TABLE 6.

Clinical response at end of treatment in patients with rIFIs

Clinical responseNo. (%) of patients
Group 1 (200 mg q.i.d./400 mg b.i.d.)Group 2 (400 mg q.i.d./600 mg b.i.d.)Group 3 (800 mg b.i.d./800 mg q.d.)Total
Efficacy evaluable (n = 9)All randomized (n = 12)Efficacy evaluable (n = 6)All randomized (n = 10)Efficacy evaluable (n = 6)All randomized (n = 10)Efficacy evaluable (n = 21)All randomized (n = 32)
Responder (complete + partial)5 (56)6 (50)1 (17)1 (10)3 (50)4 (40)9 (43)11 (34)
    Complete00002 (33)3 (30)2 (10)3 (9)
    Partial5 (56)6 (50)1 (17)1 (10)1 (17)1 (10)7 (33)8 (25)
Failure4 (44)6 (50)5 (83)9 (90)3 (50)6 (60)12 (57)21 (66)
    Stable disease1 (11)1 (8)1 (17)1 (10)1 (17)1 (10)3 (14)3 (9)
    Clinical failure3 (33)3 (25)2 (33)2 (20)1 (17)1 (10)6 (29)6 (19)
    Unable to determine001 (17)1 (10)1 (17)1 (10)2 (10)2 (6)
    Missing02 (17)1 (17)5 (50)03 (30)1 (5)10 (31)